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The low incidence of prostate cancer in Asians has been attributed to chemopreventative properties of certain chemicals found
in their diet. This study characterized the androgenic and chemopreventative properties of the Jamaican bush tea “Bizzy,” using
androgen receptor positive and negative cell lines. Exposure of prostate cells to Biz-2 resulted in a growth inhibition (GI50)o f
15ppm in LNCaP cells and 3.6ppm in DU145 cells. Biz-2 elicited a 2-fold increase in the mRNA of the anti-apoptotic gene Bcl2,
with a 10-fold increase in that of the proapoptotic gene Bax. We observed a 2.4- to 7.5-fold change in apoptotic cells in both cell
lines. Biz-2 at 10 ppm elicited a time- and dose-dependent stimulation of both the protein and mRNA levels of several androgen-
regulated genes. Biz-2 caused a 36% decrease in PSA secretion and a signiﬁcant increase in PSA mRNA. The relative binding
aﬃnity (IC50) of Biz-2 for AR was 2- to 5-fold lower than that of the synthetic androgen R1881. Biz-2 was found to be a speciﬁc
ligand for the AR in that the natural ligand, DHT, and the anti-androgen, ﬂutamide, displaced Biz-2 bound to AR and inhibited
Biz-2-induced transcription and PSA secretion. This study provided evidence that Biz-2 extract possesses the ability to modulate
prostate cancer cell biology in an AR-dependent manner.
Copyright © 2009 Rajasree Solipuram et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Nonsteroidal, plant-derived compounds that disrupt or
mimic the normal action of estradiol are referred to as
phytoestrogens. Those that disrupt or mimic the action of
testosterone or dihydrotestosterone are referred to as phy-
toandrogens. These chemicals inﬂuence endocrine activity
in animals and have been shown to play a role in the
prevention of certain hormone-dependent cancers, such as
breast and prostate cancers. The American Cancer Society
estimatedthat218,890meninUSAwouldbediagnosedwith
prostate cancer during 2007. Furthermore, they estimated
that prostate cancer would kill 33,370 men in USA in
2007, making prostate cancer the fourth leading cause of
cancer deaths in American men after lung cancer [1]. At the
same time, African Americans have the highest incidence of
prostate cancer and the highest mortality rate due to prostate
cancer of any population studied. In Asian men from China,
Japan, and Thailand, the incidence is much lower [2–4].
The low incidence of prostate disease in Eastern populations
is attributed to dietary phytochemicals such as isoﬂavones,
ﬂavones, and lignans. Epidemiological studies suggest that
the reduced risk of prostate disease in Asian populations
is associated with consumption of foods rich in soy and
v e g e t a b l ep r o d u c t s[ 5–7].
There is growing interest in using natural, dietary
plant estrogens (phytoestrogens), particularly those found
in soy products, as a potential chemopreventive regimen
for prostate cancer. Several clinical trials and biochemical
studies have been conducted to ascertain whether diets
containing high levels of phytoestrogens may provide a
chemopreventive beneﬁt for prostate cancer patients [3, 8].
Studiesanalyzingurinaryexcretionandprostaticﬂuidforthe
presenceofphytoestrogensdemonstratedthatphytoestrogen2 Journal of Toxicology
values were higher in populations exhibiting a lower prostate
cancer incidence [9, 10]. A phytoestrogen-formulated diet
reduces the number of spontaneous prostate-seminal vesi-
cle tumors in rats predisposed to prostate tumors [11,
12]. In humans, prostate cancer patients who consumed
high levels of phytoestrogens had lower levels of prostate-
speciﬁc antigen, a common marker for prostate cancer
[6, 13]. In addition, organ culture studies showed that
the phytoestrogen genistein decreased growth of prostate
cancer tissue and benign prostatic hypertrophy [14–16].
Taken together, these studies suggest that some constituent
of phytoestrogen-containing diets possesses antiandrogenic
and antitumorogenic activities, which could provide some
beneﬁcial eﬀects in prostate cancer patients [17].
Biologically active, nonsteroidal, androgenic, and estro-
genic agents are found primarily in soy products, legumes,
and whole grains. Other nontraditional sources include
medicinal teas and roots. In some cultures, natural teas
are consumed in large portions each day. Kola acuminate,
also known as Obi or Bizzy nut to the Ettu people of
Jamaica, is a “cure-all” herbal medicine. It reportedly aﬀects
many biological processes, many of which are directly, or
indirectly, modulated by hormones. Available ethnobotan-
ical information suggests that K. acuminate may contain
bioactive chemicals that possess estrogenic and androgenic
properties [18, 19]. Anecdotal reports suggest that Bizzy nut
may be useful for a number of medical purposes, such as
removal of poisons from the body, birth control, control of
diabetes,weightloss,andreliefofmenstrualcramps[20,21].
Given the hormonal dependency of some of these biological
activities, it is possible that nonsteroidal androgen present
in Bizzy nut extracts be responsible for the medicinal value
attributed to it. Recently, we identiﬁed several hormonally
active extracts of Bizzy nut that were capable of inhibiting
the growth of diﬀerent cancer cell lines [22].
In our laboratory, we are interested in natural products
such as Bizzy nut, which contain phytoestrogens, phytoan-
drogens, or compounds that are antiandrogenic in nature.
This article describes the putative androgenic eﬀects of a
Bizzy nut extract on pathways mediated by an androgen
receptor (AR) in LNCaP cells. Herein, we describe the ability
of a Bizzy nut extract to induce apoptosis in an AR-positive
cell line and to modulate AR-dependent gene expression.
2.MaterialsandMethods
2.1. Cell Culture. LNCaP and DU145 cells were obtained
from ATCC (Rockville, Md, USA). Cells were maintained in
RPMI1640(LNCaP)orKaighn’smodiﬁcationofHam’sF-12
(F12-K) medium supplemented with 10% FBS, 0.2mM glu-
tamine, 100U/mL penicillin, and 100mg/mL streptomycin.
Cells were kept in 5% CO2 in a water-jacketed incubator,
and were passaged using a trypsin/EDTA solution (Sigma-
Aldrich, Inc., St. Louis, Mo, USA) when they reached about
80–90% conﬂuency.
2.2. Pharmacological Treatments. LNCaP or DU145 cells
(1 × 105) were grown in poly-d-lysine-coated, 6-well, or
20cmplatesinCellgroserum-freemedium(Mediatech,Inc.,
Herndon, Va, USA) for 24 hours, then induced with varying
amounts of Biz-2 (ether extract) or dihydrotestosterone
(DHT). For time-course studies of induction, cells were
induced for 6, 12, and 24 hours with the appropriate
compound after which the medium was collected and
concentrated using a CentriVap concentrator (Labconco,
Kansas City, Mo, USA). The corresponding attached cells
were extracted using RIPA buﬀer (Pierce Biotechnology,
R o c k f o r d ,I l l ,U S A ) ,a n ds t o r e da t−80◦C until used. The
ether extract of Bizzy nut (Biz-2) was prepared as previously
described [22].
2.3. Cell Viability Analysis. For experiments involving cell
growth and gene induction, LNCaP cells were grown for
ﬁve days in RPMI 1640 medium containing 5% FBS that
was stripped three times with dextran-coated charcoal.
Cells were then grown for 24 hours in Cellgro serum-free
medium. Cells were plated in 96-well plates (1 × 105
cells/well) and allowed to attach overnight. The Biz-2 extract
in 0.1% DMSO was added in a series of concentrations (0–
1000ppm) to a 96-well plate. As a control and a reference,
10−7 Mgenistein(GE)or10−8 MDHTwasaddedtoseparate
wells of each plate. Each treatment and time point had eight
replicates. In each treatment, the ﬁnal concentration of
vehicle solvent did not exceed 0.01% v/v in the medium.
After 24-hour exposure to the test compounds, the eﬀect
on cell viability and gene expression was determined.
Cytotoxicity was determined by the CellTiter 96 AQueous
One Solution cell proliferation assay (Promega Corporation,
Madison, Wis, USA) according to the manufacturer’s
instructions. After incubation with 3-(4,5-dimethyl-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS), absorbance at 490nm was
measured using an ELX800UV universal microplate reader
(Bio-Tek, Inc., Winooski, Vt, USA). The cell viability was
calculated as [(A490(control)−A490(treatment))/A490(control)]×100.
For tryphan blue staining, cells were plated in 12-well plates
(10000 cells/well) and induced with 100ppm Biz-2 for 6,
12, or 18 hours. After induction, cells were harvested and
stained with tryphan blue, and the number of cells was
determined using a hemocytometer.
2.4. RNA Extraction and Real-Time RT-PCR Analysis. Total
RNA was obtained from cells treated with 0–1000ppm Biz-
2 extract, 10nM DHT, or 100nM GE in the presence or
absence of 50-fold ﬂutamide for 24 hours by lysing with
1mL of TRI reagent (Invitrogen, Carlsbad, Calif., USA). The
RNA pellet was resuspended in water, treated with RNase-
free DNase I, reprecipitated, and quantiﬁed by reading the
absorbance at 260 and 280nm on an ND-1000 spectropho-
tometer (NanoDrop Tech., Wilmington, Del, USA).
For cDNA synthesis, 5ug of DNase-I-treated total RNA
were reverse-transcribed in a 100uL reaction mixture using
the ABI High Capacity cDNA Archive Kit according to
the manufacturer’s instruction (Applied Biosystems, Foster
City, Calif, USA). The reaction contained 1X RT buﬀer,
100 uM of each deoxynucleoside triphosphate (dNTP), 1XJournal of Toxicology 3
Table 1: Regulation of androgen receptor target genes by Biz-2.
Genes
mRNA expression relative to control
Gene description Biz-2 DHT RES
10ppm–24h 10nM–24h 10nM–24h
Fold SEM N Fold SEM N Fold SEM N
PSA 10.55 2.26 3 8.09 0.91 3 3.66 0.18 3
Prostate-speciﬁc antigen: prostate tumor
marker
NKX3-1 3.932 0.74 3 13.84 2.21 3 2.51 0.24 3
NK3 homeobox: a novel human
prostate-speciﬁc, androgen-regulated
homeobox gene associated with prostate
cancer progression
TSC22 5.95 1.44 3 1.38 0.16 3 2.45 0.25 3
Tuberous sclerosis 22: a leucine zipper
transcription factor whose expression is
induced by TGF-b
PART-1 1 0.3 0.35 0.02 — — —
Prostate androgen-regulated transcript 1:
androgen-inducible gene that is regulated
by androgens and phytoestrogen
ERβ 1.17 0.4 3 1.08 0.32 3 1.27 0.21 3
Estrogen receptor β: nuclear transcription
factor that mediates transcription of
nonsteroidal and steroidal ligands
ERα 1.36 0.281 3 1.36 0.281 3 1.48 0.35 3
Estrogen receptor α: ligand-inducible
nuclear transcription factor that mediates
estrogen-dependent gene expression in
females
AR 2.84 0.20 3 1.271 0.11 3 0.44 0.01 3
Androgen receptor: transcription factor
that mediates transcription of genes
required for development of male
reproductive tissues
Bcl2 2.68 2.68 3 0.85 0.07 3 1.14 0.12 3
B cell leukemia/lymphoma-2: an
antiapoptotic protein known to regulate
apoptotic pathway and protect against
cell death
Bax 9.97 2.13 3 7.64 0.09 3 3.45 0.17 3
Bcl2-associated X-protein: a proapoptotic
protein that regulates apoptotic pathway
and promotes cell death
random primer, 5U of RNase inhibitor, and 250U of reverse
transcriptase II. The reaction was carried out at 25◦Cf o r1 0
minutes then at 37◦C for 2 hours. Control reactions were
thoseinwhichtheRTenzymeorthetargetRNAwasomitted
from the reaction.
Taqman PCR was performed on the cDNA samples using
an ABI PRISM 7500 Sequence Detection System (Applied
Biosystems). For each gene tested (see Table 1), the PCR
was carried out in a multiplex mode with every 25uL
reaction containing 2uL of cDNA reaction, 1X Taqman
universal PCR master mix, 250nM of a gene-speciﬁc primer,
250nM of an endogenous control primer, 250nM of FAM-
labeled ﬂuorogenic Taqman probe, a VIC-labeled 18S rRNA
ﬂuorogenic control Taqman probe, and 2.5U of TaqMan
enzyme. The PCR ampliﬁcation was conducted using a
Taqman Universal PCR Master Mix (Applied Biosystems) at
universal thermal cycling conditions: 50◦Cf o r2m i n u t e s ,
95◦C for 10 minutes, 40 cycles at −95◦C for 15 seconds, and
60◦C for 1 minute. An increase in ﬂuorescence was obtained
at the annealing and extension step at 60◦C.
The relative level of expression of each gene in the
samples was determined using the relative 2ΔΔCt expression
method as described in detail in the ABI PRISM Sequence
Detection System User Bulletin 2 [23]. After the linear range
of ampliﬁcation (threshold cycle, Ct) was determined for the
genes of interest, it was normalized against an endogenous
18S rRNA control and then against the untreated control
sample, which served as the calibrator. The value of the
relative level of expression for the gene of interest represents
two independent inductions performed in triplicate.
2.5. Ligand Binding Analysis. The binding aﬃnity of Biz-2 to
the Androgen receptor was evaluated on whole-cell, LNCaP
extract or on 10nM of the baculovirus-expressed ligand
binding domain of the AR (PanVara, Madison, Wis, USA)4 Journal of Toxicology
[24, 25]. Samples (100uL) containing 250ug of total protein
in 1X binding buﬀer (10mM HEPES, pH 7.9, 10% glycerol,
0.02% Ficoll 400, 100mM NaCl, 0.1mM EDTA, 2.5mM
for each of MgCl2,C a C l 2, and DTT, and 1g/mL for each
of leupeptin, pepstatin, antipain, aprotinin, soybean trypsin
inhibitor, and chymostatin) were incubated with 2nM [3H]-
R1881 in the presence or absence of a 10-fold serial dilution
of 10000ppm Biz-2, for 18 hours at 4◦C. Free and bound
radioligands were separated using the hydroxyapatite assay.
Boundradioligandwasmeasuredbyscintillationcountingas
previously described [26]. Speciﬁc binding was determined
by subtraction of nonspeciﬁc binding from total binding.
The IC50 (the concentration of competitor that results in
50% of maximal binding) and Ki (the competitor binding
constant assuming 1nM Kd for radiolabeled ligand) were
determined by ﬁtting the data to the Cheng-Prusoﬀ equation
[27] using the Prism III software program (GraphPad, San
Diego, Calif, USA).
2.6. Fluorescence Microscopy. For microscopy, 5 × 105 cells
(LNCaP or DU145) were grown on microscope slides and
induced with 0, 100, and 500ppm of Biz-2 for 24 hours.
On each slide, cells were stained for 5 minutes with 5μL
of a 0.1ug/uL solution of acridine orange and ethidium
bromide. Two ﬂuorescence parameters, green emission from
acridine orange (525nm) and red emission from ethidium
bromide(620nm),wereexamined under aﬂuorescencelight
microscope (Nikon Optiphot, Melville, NY, USA) for the
nuclear changes that are typically associated with apoptosis.
An index of apoptosis was calculated as the ratio of the
number of cells per microscopic ﬁeld with early and late
apoptosis characteristics in treated samples relative to the
total number of cells per microscopic ﬁeld.
2.7. Analysis of Caspase 3/7 Activation. Caspase 3/7 activity
was determined using an Apo-One Homogeneous Caspase-
3/7 Assay kit (Promega Corporation) according to the
manufacturer’s instructions. Brieﬂy, cells were grown in test
medium to a density of 1 × 106 cells/mL. The cells were then
treated with Biz-2, antigen, or a combination of the two, as
indicated, for 12 or 24 hours. Following induction, cells were
harvested by incubation in 5mL of harvesting solution at
37◦C for 5–10 minutes. The cells were collected by centrifu-
gation. The pellets were resuspended in 100uL of hypotonic
cell lysis buﬀer (25mM HEPES, pH 7.5, 5mM MgCl2,5m M
EDTA, 5mM DTT, and 2mM PMSF). The samples were
subjectedtotworoundsoffreezingandthawinginliquidN2,
then centrifuged at 14000 × g for 15 minutes. Caspase 3/7-
like activity was determined based on proteolytic cleavage of
rhodamine 110, bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-
L-aspartic acid amide, Z-DEVD-R110). The free rhodamine
110 was quantiﬁed on a SpectraMax Gemini Fluorescence
Spectrophotometer with excitation at 499nm and emission
at 521nm using the SoftMax Pro program in static mode.
The Caspase 3/7-like activity in each sample was determined
from the maximum ﬂuorescence after 3 hours. Recombinant
Caspase 3 served as a positive control for the assay.
2.8. Western Blot Analysis. Immunoblot of the LNCaP pro-
tein fraction was performed as previously described [28, 29].
Brieﬂy, LNCaP cells grown under the indicated condition
were lysed at 4◦Ci nR I P Ab u ﬀer supplemented with 1X
sigma protease inhibitor cocktail (Sigma-Aldrich, Inc.). A
BCA protein assay kit (Pierce Biotechnology) was used to
determine protein concentration. An aliquot of the total
protein sample (30ug) was size-fractionated using a 10%
or a 4–20% precast (SDS-PAGE) gel (Pierce Biotechnol-
ogy), then the fractionated proteins were transferred to a
polyvinylidene diﬂuoride (PVDF) membrane (Immobilien,
Millipore, Bedford, Mass, USA). The membrane was blocked
with 5% nonfat dry milk in TBST buﬀer (10mM Tris-
HCl, pH 8, 150mM NaCl, and 0.1% Tween-20) for 1
hour at room temperature, and immunostained with the
following antibodies: 0.5ug/mL anti-Bcl2 and 0.5ug/mL
anti-Bax (Santa Cruz Biotechnology Inc., Santa Cruz, Calif,
USA), 1.5ug/mL anti-AR and 0.5ug/mL anti-GDPH (Cell
Signaling, Danvers, Mass, USA). The blots were washed
three times with TBST buﬀer, and immunoreactive proteins
were detected using a 1 : 20,000 dilution of antirabbit IgG
horseradish peroxidase (Amersham, Arlington Heights, Ill,
USA) at room temperature for 1 hour. The bands were
visualized using an enhanced chemiluminescence detection
system (Pierce Biotechnology) according to the instructions
of the manufacturer. The immunoblot signal was captured
using an AlphaInnotech Fluorochem HD 9900 (AlphaIn-
notech, San Leandro, Calif, USA) equipped with a CDD
camera. The images were analyzed with the AlphaEaseFC
software (AlphaInnotech), and curves and graphs were ﬁtted
with GraphPad Prism 3.0 software (GraphPad) [30].
2.9. Analysis of PSA Secretion by Immunoassay. The total
amount of prostate-speciﬁc antigen (PSA) secreted by
LNCaP cells was quantiﬁed under diﬀerent experimental
conditions using a two-site sandwich, colorimetric base
ELISA kit according to the manufacturer’s instructions (CBI
PSA ELISA kit, Calbiotech, Inc., Spring Valley, CA, USA).
Brieﬂy, 1 × 107 cells were treated with Biz-2, phytoestrogen,
or DHT as indicated. The conditioned medium was removed
and centrifuged at 12000rpm for 5 minutes to remove any
detached cells. An aliquot of the medium (1 or 10uL) was
added to each well of a 96-well plate, precoated with anti-
PSA antibody. The unbound PSA in the sample was allowed
to bind. The unbound PSA was then removed by washing.
The horseradish peroxidase-labeled PSA enzyme conjugate
was added for 30 minutes followed by the addition of the
colorimetric terminating message buﬀer substrate, and the
color change was read at an absorbance of 570nm using
an ELX800UV universal microplate reader (Bio-Tek, Inc.).
To quantify the relationship between absorbance and the
concentration of PSA, a standard curve (0–50ng/mL) was
prepared from PSA solutions of known concentration. The
results were expressed as nanograms of PSA per mL of
conditioned medium, and were adjusted to nanograms per
mg of secreted protein.
2.10. Determination of Cell Proliferation Using Thymidine
Incorporation. Thymidine incorporation was measured as
previously described [28]. Brieﬂy, cells were plated at a
density of 1 × 104 cells/well in 96-well plates, and incubatedJournal of Toxicology 5
overnight. Biz-2 in 0.1% dimethyl sulfoxide was added
at a series of concentrations (0–1000ppm) to eight wells
each of a 96-well plate, and incubated for 24 hours. After
adding 0.5 uCi/well of [methyl-3H]Thymidine, plates were
incubated for 6 hours. The medium was removed and cells
were harvested onto a Whatman 934-AH glass microﬁber
ﬁlter (Fisher Scientiﬁc, Pittsburgh, Pa, USA) using a 96-well
ﬁltration manifold. To lyse the cells, ﬁlters were washed with
0.2mM NaOH. Filters were then washed with 70% ethanol
and dried with 95% ethanol. The ﬁlter paper was cut into 96
distinct pieces, placed in scintillation vials containing 3mL
of liquid scintillation ﬂuid (MP Biomedicals, Solon, Ohio,
USA),andcountedinaTriCarb2200CAscintillationcounter
(Packard, Medien, Conn, USA).
2.11. Solid-Liquid Extraction and TLC Analysis. A1 0 g
sample of ﬁnely ground Bizzy root wassequentially extracted
in a Soxhlet apparatus using 500mL of 100% hexane,
ether, acetone, methane, or water, solvents with increasing
polarity. The extraction mixture was allowed to reﬂux for
24 hours at temperatures corresponding to the boiling
point of the respective solvent and the extraction monitored
by TLC chromatography. Following extraction, particulate
matter was removed by ﬁltering the samples through a
0.45μm glass-fritted ﬁlter, and the extract was evaporated to
dryness using a combinationof simple distillation and rotary
evaporation. The residue of each extract was resuspended in
DMSOtoaconcentrationof10000ppm.Aliquots(100ppm)
ofeachextractwererunonthin-layerchromatographyplates
( S i l i c aG e lH l ,A n a l t e c h ,N e w a r k ,D E ,U S A ;c a .1 0c mw i d e
× 20cm high) using a solvent of 40% v/v Ether-60% v/v
Hexane. The analytes were visualized under ultraviolet light,
and the image was captured digitally using a FluorChem HD
Alpha Innotech System.
2.12. Statistical Analysis. All numerical data were expressed
as mean ±SEM. In each assay, three or four measurements
were made. Means for the treatment groups were compared
using analysis of variance and Duncan’s multiple range test
(P<. 05). To analyze the absorbance density from western
blot data, a two-tailed t-test (P<. 05) was used to compare
the mean (n = 3) for each treatment group with the mean
for the untreated control group. The GraphPad Prism 3.0
software program (GraphPad) was used for the statistical
analyses [30].
3. Results
3.1. Activation of an Androgen-Dependent Pathway by Biz-
2. The androgenic potential of natural compounds is mani-
festedinavarietyofbiologicalresponsesincludinginduction
of cell growth, secretion of cellular protein, and receptor-
dependent gene expression. Secretion of PSA by the prostate
isahallmarkofprostaticfunction.Furthermore,modulation
of PSA level is used as a biomarker in assessing prostate
development and function. As an initial step in identifying
and characterizing medicinally relevant, putative, selective
androgen receptor modulators (SARMs) present in Bizzy
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Figure 1: Biz-2 modulates PSA secretion by LNCaP cells. LNCaP
cells (1E7) were grown in serum-free medium for 24 hours,
then induced with 100ppm of Biz-2 for 0, 6, 12, and 24 hours.
Equal aliquots (10uL) of the condition medium were removed
and analyzed by PSA ELISA (see Section 2). (a) Time-dependent
secretion of PSA. (b) PSA secretion induced with 10ppm Biz-
2 for 24 hours in the presence and absence of 10nM ﬂutamide.
The values are the mean ± SEM of three separate experiments
performed in triplicate. CON: control; DHT: dihydrotestosterone;
Biz-2: ether extract of Bizzy nut; RES: resveratrol.6 Journal of Toxicology
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Figure 2: Stimulation of PSA mRNA expression by Biz-2. LNCaP cells were induced with Biz-2 or DHT, and 5μg of DNase-I-treated RNA
isolated from induced or uninduced cells were subjected to two-step Taqman real-time RT-PCR (see Section 2). The relative expression of
PSA mRNA expression was calculated by the 2ΔΔCt method. First, relative quantitation of PSA mRNA expression was performed by ﬁrst
normalizing the Ct values of PSA ampliﬁcation against the Ct values of endogenous 18S rRNA, then the resulting Ct values were normalized
using the Ct value of the vehicle control sample. (a) Relative ampliﬁcation plot of mRNA expression (1–NTC. 2–18S rRNA at 24 hours, 3
and 4- CON at 6 and 24 hours, 5 and 6- Biz-2 at 6 and 24 hours). (b) PSA mRNA expression relative to time. (c) Dose-dependent response
of PSA to Biz-2. The values are mean ± SEM of induction samples analyzed in triplicate.
nut, we performed solid-liquid extraction using solvents of
increasing polarity. We screened each extract for bioactivity
usingseveralinvitroassaysthatweredesignedtorevealifany
of the extracts contained androgenic or estrogenic activity
[22]. We determined whether an ether extract of Bizzy nut
(Biz-2) was capable of modulating prostate function by
exerting its eﬀect on PSA secretion by LNCaP cells. LNCaP
cells were grown in a serum-free medium for 24 hours, and
then induced with 100ppm of Biz-2 for 6, 12, or 24 hours.
A PSA ELISA was then used to determine the concentration
of PSA in the medium. PSA secretion by LNCaP cells in the
presenceofBiz-2displayedabiphasicresponse(Figure 1(a)).
Relative to control, Biz-2 induced an initial 26.59 ± 13.3%
increase in PSA after the ﬁrst 6 hours of exposure. The level
of PSA decreased by 32.6 ± 1.3% during the second six-
hour period, and increased by 25.93 ± 3.3% 12 hours later
(Figure 1(a)). In contrast, DHT produced a time-dependent
increase (9.6 ± 6.7% and 130 ± 6% after 12 and 24 hours,
resp.) in PSA production under the same experimental
conditions (Figure 1(a); data not shown).
To understand the relationship between Biz-2 modula-
tion of PSA secretion and the androgen-dependent pathway,Journal of Toxicology 7
we determined whether the PSA secretion was mediated
by a Biz-2/androgen receptor interaction. To answer this
question, PSA secretion was measured in the presence of the
antiandrogen ﬂutamide (FLU) (Figure 1(b)). As a positive
control, we measured PSA secretion in the presence of
ﬂutamide with or without the natural androgen, DHT.
Consistent with previous studies [31, 32], ﬂutamide blocked
the AR-dependent stimulation of PSA (1.014 ± 0.08ng/uL
for DHT versus 0.549±0.07ng/uL for DHT/FLU) by LNCaP
cells. Treatment of LNCaP cells with 10ppm Biz-2 plus 1nM
of ﬂutamide prevented the Biz-2 inhibition of PSA secretion
(Figure 1(b)). At 10ppm Biz-2, PSA levels decreased by
24.80 ± 3.4% of control, that is, from 0.654 ± 0.01ng/uL to
0.492 ± 0.022ng/uL. Addition of ﬂutamide at 1nM restored
the PSA level to that of control (0.673 ± 0.077ng/uL Biz-
2/FL Uversus0.654±0.03ng/uLcontrol).Inoursystem,there
was a signiﬁcant increase (16 ± 2.8%, n = 8, P<. 01) in
PSA secretion in the presence of FLU, suggesting that there
may have been residual androgen present in the medium.
Alternatively, ﬂutamide may have induced an androgenic
eﬀect on PSA under serum-free conditions (Figure 1(b)).
Nevertheless, FLU was able to prevent the Biz-2-induced
decrease in PSA secretion, which was an observation that
was complimentary to what we observed with DHT/FLU
treatment. These results strongly suggested that the Biz-
2 inhibition of PSA secretion was dependent on the AR
pathway.
3.2. Transcriptional Inhibition of an Endogenous Androgen-
R e g u l a t e dG e n eb yB i z - 2 .Modulation of PSA secretion in
the presence of Biz-2 may have resulted from changes in
PSA mRNA production, and could have been independent
of the secretion processes that were present in LNCaP
cells. To test this hypothesis, we measured PSA mRNA
levels in cells exposed to Biz-2 using Taqman real-time
RT-PCR. Multiplex real-time PCR was performed using a
primer/probe set speciﬁc for PSA and 18S rRNA (PE Applied
Biosystems, Foster City, Calif, USA). The expression levels
of PSA were obtained from DNase-I-treated total RNA, and
were normalized to those of the 18S rRNA gene, which
served as the calibrator for our experiments. The logarithm
oftheﬂuorescenceintensityofeachprobeversusthenumber
of cycles and the level of expression of mRNA of PSA
in LNCaP cells was evaluated (Figure 2). In the present
study, the mRNA expression of PSA was determined using
the 2ΔΔCt method, and is expressed relative to the control
sample which is set to 1. We observed a time-dependent
i n c r e a s ei nl e v e l so fP S Am R N Ab e t w e e n6a n d2 4h o u r s
of exposure in the presence of 10ppm Biz-2 (Figure 2(b)).
Analysis of the data in Figure 2(b) also indicated that, after
treatment with Biz-2 or the positive control (DHT), levels
of PSA mRNA expression showed a statistically signiﬁcant
increase. Exposure of LNCaP cells to 10ppm Biz-2 resulted
in a 0.87 ± 0.17-fold increase in PSA mRNA, which was
increased by 12-fold (0.87 ± 0.17 to 10.56 ± 2.25) in the
second 12-hour period. We determined the potency of Biz-
2 in stimulating PSA mRNA by exposing LNCaP cells to
diﬀerent amounts of Biz-2 for 24 hours. The response of
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Figure 3: Flutamide inhibition of Biz-2 stimulation of PSA mRNA
expression. LNCaP cells were induced with Biz-2 in the presence
or absence of ﬂutamide, and RNA from induced or uninduced
cells was subjected to two-step Taqman real-time RT-PCR. Rel-
ative quantitation of PSA mRNA expression was preformed as
described in Figure 2. CON: vehicle control; FLU: ﬂutamide; Biz-2:
Bizzy nut extract-2; RES: resveratrol; Act.D: actinomycin-D; CHX:
cycloheximide. The values are the mean ± SEM of three separate
experiments performed in triplicate.
PSA mRNA production to Biz-2 concentration was bell-
shaped (Figure 2(c)). At concentrations below 10ppm, Biz-2
elicited a dose-dependent increase in PSA mRNA expression,
w h e r e a sa th i g hc o n c e n t r a t i o n s( 1 0 0 p p ma n dg r e a t e r )
expression of PSA was inhibited. Biz-2 at low concentrations
produced a similar increase in PSA mRNA at 12 and 24
hours as the endogenous androgen DHT (Figure 2(b);d a t a
not shown).
To substantiate the observation that Biz-2 modulated
PSA activity in an AR-dependent manner, we measured Biz-
2-induced PSA mRNA in the presence of the AR antagonist
ﬂutamide. The Biz-2-induced expression of PSA mRNA was
inhibited by 55% (3.46 ± 0.25-fold Biz-2 to 1.55 ± 0.14-
fold Biz-2/Flu) in the presence of 1nM ﬂutamide (Figure 3)
suggesting that Biz-2 mediated an increase in PSA mRNA
level through an interaction with the AR present in LNCaP
cells. On the other hand, resveratrol, a phytoestrogen with
bioactivityinLNCaPcells,induceda1.5-foldincreaseinPSA
mRNA levels, which was independent of the AR (Figure 3).
Next we ascertained whether the stimulatory eﬀects of Biz-
2 on PSA expression were a result of RNA stability by
measuring the mRNA levels of PSA in the presence and
absence of actinomycin-D, a known transcription inhibitor.
Pretreatment of LNCaP cells with 5ug/uL of actinomycin-D
for 4 hours resulted in a 26% inhibition of PSA expression
relative to Biz-2. At the same time, blocking of protein8 Journal of Toxicology
synthesis using cycloheximide resulted in an increase in
the Biz-2-induced expression of PSA (Figure 3). Because
actinomycin-D alone could not have induced PSA mRNA
synthesis, our data suggested that Biz-2 regulated PSA
expression directly at the level of transcription.
3.3. Modulation of AR-Dependent Gene Expression by Biz-
2. To further characterize the eﬀects of Biz-2 on the AR-
dependent pathway, we examined the androgenic eﬀects
of Biz-2 on the transcription activity of three androgen-
regulated genes (PSA, PART-1, and NKX3-1) [33–35]a n d
three steroid receptor genes (ER-β,E R α,a n dA R )[ 36, 37]
using real-time, quantitative, two-step RT-PCR (Table 1).
Biz-2 produced a robust induction in the three androgen-
regulated genes tested (Table 1). We ascertained the speci-
ﬁcity and the strength of induction of androgen-speciﬁc
genes by Biz-2 by determining the relative gene expression
at 10ppm Biz-2 or 10nM DHT. We observed that Biz-2
was as eﬀective as DHT in inducing the expression of the
well-known prostate-speciﬁc gene (PSA). Biz-2 at 10ppm
produced 10.55 ± 2.2-, 3.9 ± 0.74-, and 5.95 ± 1.4-fold
inductions of PSA, NKX3-1, and TSC22 mRNA levels,
respectively. Relative to DHT, Biz-2 was six times more
eﬀective in stimulating TSC22 expression (Table 1). Biz-2
showed a marginal increase in expression levels of steroid
receptor genes (ERα:1 .4 ± 0.3; ERβ:1 .2 ± 0.4; AR: 2.8 ±
0.2) suggesting diﬀerential regulation of androgen-regulated
genes by Biz-2 in LNCaP cells (Table 1). Biz-2 was able to
stimulate each prostate-speciﬁc, AR-dependent gene 2-fold
to 8-fold relative to control. Taken together, we surmised
that Biz-2 had a major inﬂuence on AR-dependent gene
activation in LNCaP cells.
3.4. Components of Bizzy Nut Extract that Bind to the AR
with High Aﬃnity. To corroborate our gene expression data
and to provide further evidence that the eﬀects of Biz-2 are
AR-mediated, we measured the ability of Biz-2 to bind to
the AR. We examined the ability of Biz-2 to compete with
3[H]R1881 for binding to AR using puriﬁed, recombinant-
expressed AR, LNCaP cells, which contained high levels
o ft h em u t a t e df o r mo fA R[ 38], or cells transfected with
the wild-type pCMV-AR expression plasmid. A pCMV-AR
expression plasmid was transfected into either LNCaP or
DU145 cells, and the ability of the transfected cells to bind to
Biz-2 speciﬁcally was measured using a competition receptor
bindingassay[28,39].LNCaPcellswerechosenbecausethey
are AR-positive. The DU145 cells were chosen as a null envi-
ronment because they are AR-negative. The concentration of
Biz-2 that reduced the speciﬁc binding of 3[H]R1881 by 50%
(IC50) was determined by incubating protein obtained from
transfectedandnontransfectedcellswith2nM 3[H]R1881in
the absence and presence of increasing concentration of Biz-
2. Biz-2 was able to displace 3[H]R1881 bound to the mutant
androgen receptor in LNCaP cells, puriﬁed recombinant
receptor,orthewild-typereceptorprotein(Figure 4(a)).Biz-
2 displayed high-aﬃnity binding to both the mutant and the
wild-type AR, suggesting that the T877A mutation of the
LNCaPARwasnotresponsiblefortheBiz-2/ARbiology.The
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Figure 4: Biz-2 competes for AR binding in LNCaP cells. AR
protein from LNCaP cells, cells transfected with pCMV-AR, or
puriﬁed recombinant AR protein was incubated with 2nM [3H]
R1881 with or without increasing concentration of Biz-2 for 18
hours at 4◦C. Bound and free [3H] R1881 were separated using the
HAP assay (see Section 2). Each data point represents the mean ±
SEM of a representative experiment performed in triplicate. The
IC50 was calculated from the competition curve using a one-site
competitionmodel.Ki wascalculatedbyKi =IC50/(1+[ligand]/Kd)
in which Kd and ligand concentration [ligand] were set to 1 and
2nM, respectively. (a) Single-point assay in the presence of 500X
excess R1881 (number above the bar is % of total binding). (b)
Displacement curve of [3H] R1881 by Biz-2 (insert is displacement
curve of [3H] R1881 by inert R1881). N = 2 separate experiments
performed in triplicate.Journal of Toxicology 9
AR binding aﬃnity (IC50 and Ki) of Biz-2 was determined
from the competition assay, because the assay was performed
under conditions where the 3[H]R1881 and the competing
Biz-2 were not depleted. The IC50 and apparent Ki for Biz-
2 binding to AR were obtained by ﬁtting the radioligand
competitive data to the Cheng-Prusoﬀ equation [27]. The
IC50 was determined from nonlinear regression of the data
ﬁtted to a one-site competition binding, where the Kd
for 3[H]R1881 binding to AR was assumed to be 1nM
(Figure 4(b)). The calculated Ki and IC50 for Biz-2 binding
to the wild-type or LNCaP AR were 26.45 (CI 17.85 to 39.20)
and 52.91 ±1.69ppm (P<. 05), respectively. Comparison of
the Ki of Biz-2 to that of R1881 binding to the AR suggested
that Biz-2 was only 13X less potent in binding to the AR.
3.5.ComponentsofBiz-2ExtractareInhibitorytoProliferation
of LNCaP Cells. Biz-2 at high concentrations reduced PSA
secretion by LNCaP cells, but increased PSA mRNA levels.
At these high concentrations, components of Biz-2 may have
induced necrotic or apoptotic events in LNCaP cells. To test
this hypothesis, we determined whether Biz-2 exerted any
cytotoxic eﬀects using MTT viability and a 3[H]-thymidine
proliferation assay. The cytotoxicity of Biz-2 was determined
in both the AR-positive LNCaP and AR-negative DU145
cells. Biz-2 at less than 20ppm was capable of inducing
cell death (proliferation inhibition) in more than 50% of
LNCaP cells (Figure 5). In addition, Biz-2 was more eﬀective
in inducing death in DU145 cells at the concentrations tested
(Figure 5(a)). Next we determined the potency of Biz-2 in
inhibiting survival of LNCaP and DU-145 cells. The GI50
of Biz-2 was determined by plotting the thymidine data
as a dose-response curve with a variable slope. Maximal
inhibition of LNCaP cell growth by Biz-2 was achieved at
50ppm with a GI50 of 14.69 ± 1.16ppm (Figure 5(a)). Biz-
2 was ﬁve times more potent in the androgen-independent
cell line, DU145, than in the LNCaP cells. Both MTT and
tryphan blue staining demonstrated a signiﬁcant decrease in
cell viability after 6 hours at 100ppm Biz-2 (Figure 5(b)).
Biz-2 induced 31.44% and 35.63% decreases in LNCaP
cell viability and cell number, respectively (Figure 5(b)).
To corroborate the 3[H]-thymidine incorporation assay, we
evaluated the eﬀect of Biz-2 on LNCaP cell proliferation
using MTT exclusion as an index of cell cytotoxicity. Within
24 hours of exposure to Biz-2, cell viability decreased with
dose(Figure 5(c)).Thisdecreasewassimilartothatobserved
with the thymidine incorporation assay (Figure 5(a)). The
lethal dose concentration (LD50) and the growth inhibitory
concentration (GI50) of Biz-2 on LNCaP cells were 14.69 ±
1.16ppm and 15.24±0.24ppm in the MTT and [3H] thymi-
dine incorporation assays, respectively. Taken together, these
results suggested that in LNCaP cells, high concentration of
Biz-2elicitsacytotoxiceﬀectthatistime-dependentandmay
reduce cell proliferation and increase the frequency of cell
death.
3.6. Biz-2-Induced Apoptosis and Cell Cycle Arrest in LNCaP
Cells. Our current data suggest that in AR-positive LNCaP
cells, Biz-2 is cytotoxic, which presumably leads to inhibition
of cell proliferation. Therefore, we examined the mechanism
of Biz-2 cytotoxicity. We investigated whether the observed
cytotoxicitywasaresultofachemicallyinducedcellularcyto-
toxicity or cell-induced apoptosis. We hypothesized that Biz-
2 could be cytotoxic because it ruptures plasma membranes.
That is, we hypothesized that a necrotic reaction, but not
programmed cell death, was responsible for the cytotoxity
of Biz-2. Therefore, we examined whether the initial cellular
cytotoxicity of Biz-2 was related to the extent of apoptosis.
LNCaP cells (5 × 105) were grown, induced with increasing
concentration (0.1–100ppm) of Biz-2, and prepared for
microscopic examination as described in Section 2. Slides
were examined under a ﬂuorescent light microscope for the
nuclear changes that are typical of apoptosis. Microscopic
examinationofapoptoticcellsrevealedthattherewasadose-
dependent increase in apoptosis of both LNCaP and DU145
cells following 24-hour exposure to Biz-2. Examination of
cellstreatedwithBiz-2byphase-contrastmicroscopyshowed
a dramatic decrease in cell number and cellular shrinkage
(Figures 6(a) and 6(b)). Fluorescence staining with acrydine
orange and ethidium bromide revealed signs of nuclear con-
densation, nuclei fragmentation, and membrane budding,
which are all hallmark features of apoptosis (Figures 6(a)
and 6(b), bottom panels). Light microscope analysis of cells
indicated that at 1 and 100ppm Biz-2, 24%–65% cell death
occurred in LNCaP cells, whereas, only 5%–15% cell death
was observed in DU145 cells after a 24-hour exposure. The
apoptotic index wasdetermined forboth LNCaP and DU145
by quantifying the relationship between dose of Biz-2 and
apoptosis (Figure 6(c)). We calculate the apoptotic index by
averaging the number of apoptotic cells per ﬁeld (70–60
cells) then dividing by the total number of cells per ﬁeld
(120–140 cells). In the case of LNCaP cells, apoptosis was
strongly related to cytotoxicity (Figures 5 and 6(c)). We
observed a greater degree of apoptosis in the AR-positive
LNCaP cells as compared to the AR-negative cell, DU145.
A concentration of Biz-2 of 10ppm induce 20–25 ± 3%
apoptosis in LNCaP as compared to 10–12 ± 4% in DU145
cells. As the concentration of Biz-2 was increased to 10 and
100ppm, the frequency of apoptotic cells increased in both
cell lines (Figure 6(c)).
3.7. Bizzy Nut Extract Induces Activation of Early Apoptosis
Gene. To gain an understanding of the relationship between
Biz-2-induced cytotoxicity and apoptosis, we examined the
expression of several key apoptosis genes. The temporal
dynamics of Bcl2 and Bax during Biz-2-induced cytotoxicity
in LNCaP cells was assessed using western blot analysis
and QRT-PCR. Bcl2 protein was detectable in LNCaP cells
grown in serum-free medium for 48 hours. Induction with
0.1ppm of Biz-2 resulted in a 4-fold increase in Bcl2 protein
and mRNA (Figure 7(a) and Table 1). Following the initial
stimulation by Biz-2, the decrease in Bc12 protein expression
was dose-dependent. The decrease in Bcl2 levels with the
increase in Biz-2 probably was not due to metabolism
of this compound, because there was a time-dependent
increase in Bcl2 at 10ppm Biz-2 (data not shown). Similarly,
when we analyzed the dose-dependent expression of the10 Journal of Toxicology
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Figure 5: Modulation of prostate cell proliferation by Bizzy nut extracts. LNCaP or DU145 cells were grown in the presence of 0–1000ppm
Biz-2 for 24 hours, and cell growth was determined using (a) 3[H] thymidine incorporation, (b) MTT cell viability assay and tryphan blue
dye staining, and (c) cytotoxicity of Biz-2 in LNCaP cells that was performed as described in Section 2. Growth inhibitory activity of the
extractswasdeterminedas[(A490(control)−A490(extract))/A490(control)]×100.Eachvaluerepresentsmean ±SEMforthreeexperimentsperformed
in eight wells of a 96-well plate. Values followed by ∗ P<. 05 diﬀered signiﬁcantly from the controls.
proapoptotic protein Bax in the presence of Biz-2, there
was a slight increase (0.5–1.3-fold) in Bax protein and a
dramatic increase (9.97-fold as compared to control) in its
mRNA expression within the ﬁrst 12–24 hours of exposure
(Figure 7(a) and Table 1). The decrease in both Bax and Bcl2
proteins after 24-hour exposure to 100ppm Biz-2 appeared
to be related to the time-dependent decrease in both proteins
(Figure 7(a); data not shown). Because the Bax and Bcl2
protein levels were important in the release of a key factor
early in the apoptotic cascade, we determined the Bax/Bcl2
ratio in the presence of Biz-2. Bax/Bcl2 levels decreased with
increasing concentration of Biz-2. At a high concentration,
the LNCaP appeared to recover from the initial apoptotic
event induced by Biz-2.
We validated the morphological analysis and protein
assessment of Biz-2-induced apoptosis by ascertaining if
the protein activity of the downstream apoptotic protein
Caspase 3/7 had been modulated in the presence of Biz-2.
The level of active Caspase-3 was measured by proteolytic
cleavageofrhodamine110,fromthebis-(N-CBZ-L-aspartyl-
L-glutamyl-L-valyl-L-aspartic acid amide) (Z-DEVD-R110)
substrate. There was a dose-dependent increase in Biz-
2-induced cytotoxicity in LNCaP cells (0.1–10ppm) as
evidenced by the 2.5-fold increase in Caspase 3/7 activityJournal of Toxicology 11
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Figure 6: Cellular and nuclear morphology indicative of apoptosis induced by Biz-2. LNCaP cells were grown on a microscope slide, then
induced with 1 or 100ppm of Biz-2 for 24 hours. Cells were stained with a solution of acridine orange and ethidium bromide for 5 minutes,
then examined by light microscopy. (a) Confocal laser ﬂuorescent microscope images taken with a 550nm ﬁlter (Top panel: acridine orange,
middle panel: ethidium bromide, bottom panel: both). (b) Apoptotic index was determined. We calculate the apoptotic index by averaging
the number of apoptotic cells per ﬁeld (70–60 cells), then dividing by the total number of cells perﬁeld (120–140 cells) (total number of cells
− total number of apoptotic cells)/(total number of cells).12 Journal of Toxicology
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Figure 7: Modulation of apoptotic protein levels in the presence of Biz-2. LNCaP cells were grown in a serum-free medium in the presence
of increasing concentrations of Biz-2 for 24 hours. Whole-cell extracts were isolated with RIPA buﬀer, and 30μg of protein extract were
analyzed by immunoblotting for Bcl-2, Bax, AR, and GDPH expression. (a) Immunoblot of Biz-2-induced proteins. (b) Ratio of Bcl2/Bax
expression. (c) Biz-2 induces increase in Caspase 3/7 activity.
relative to the untreated control (Figure 7(c)). In the analysis
of time-dependent Caspase 3/7 activity in the presence of
100ppm Biz-2, Caspase 3/7 activity decreased signiﬁcantly
relative to the untreated control within the ﬁrst 6 hours of
induction, which suggested that a high concentration of Biz-
2 inhibited apoptosis in LNCaP cells (Figure 7(c);d a t an o t
shown).
3.8. Biz-2 Modulation of Apoptotic Pathway in LNCaP Cells
is Mediated through an AR Pathway without New Protein Syn-
thesis. Weusedtheproteinsynthesisinhibitorcycloheximide
(CHX) and the AR antagonist ﬂutamide (FLU) to investigate
(a) whether Biz-2-induced apoptosis required protein syn-
thesis and (b) if Biz-2-induced apoptotic processes use an
AR signaling pathway (Figure 8). Treatment of LNCaP with
1ug/mL of CHX for 12 hours after induction with 100ppm
Biz-2 resulted in an inhibition of Biz-2-induced Caspase 3/7
activity and Bax, and Bcl2 protein expression (Figure 8(b);
data not shown). At low concentration, Biz-2 stimulated
Caspase 3/7 activity 1-2-fold. CHX completely abolished
the Biz-2-stimulated Caspase levels, which suggested that
the eﬀect of Biz-2 on Caspase required protein synthesis.
The analysis of Caspase 3/7 activity and Bax expression in
the presence and absence of actinomycin-D implied that
Biz-2 did not elicit a direct transcription eﬀect on Bax or
Caspaselevelsbecausepretreatmentwithactinomycin-Dhad
no eﬀect on their expression (Figure 8(b);d a t an o ts h o w n ) .
To corroborate the CHX data and to generate further
evidence that Biz-2-modulated apoptosis in LNCaP cellsJournal of Toxicology 13
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Figure 8: Biz-2 increases Caspase 3/7 levels in LNCaP cells. LNCaP
cells (1 × 106) were grown in test medium and induced with
100ppm Biz-2 for 24 hours, and the resulting Caspase 3/7 activity
was determined using the Apo-One Homogeneous Caspase-3/7
assay as described in Section 2. (a) Western blot of Bcl2 and Bax
proteins following induction of LNCaP with Biz-2 in the absence
and presence of ﬂutamide. (b) Caspase 3/7 activity was expressed as
n-fold increase relative to untreated control (n = 8, mean ± SEM).
involved transcriptional regulation through an androgen-
dependent pathway, we measured the expression of Bax
and Bcl2 and Caspase 3/7 activity in the presence of the
AR antagonist ﬂutamide. Bcl2 protein levels and Caspase
activity decreased in the presence of 1nM FLU, which
suggestedthattheantiandrogenprotectedprostatecellsfrom
apoptotic assaults (Figure 8). At 10ppm Biz-2, there was
an 80% decrease in Caspase 3/7 activity in the presence of
FLU (Figure 8(b)). FLU produced up to a 2-fold decrease
in Bcl2 protein but had a notable 2-fold increase on Bax
protein levels (Figure 8(a)). As with the Caspase 3/7 activity,
cotreatment of Biz-2 with FLU completely blocked Biz-2-
induced increases in Bcl2 and Bax proteins. To substantiate
the FLU data, we measured Bcl2-protein levels in the
presence of resveratrol, which induces apoptosis in LNCaP
cells [40]. Resveratrol-induced inhibition of Bcl2 and Bax
expression was completely blocked by FLU (Figure 8(a)).
Thus, the cytotoxic eﬀect of Biz-2 on LNCaP cells was
decreased by more than 90% in the presence of CHX or the
antiandrogen FLU, and was unaﬀected by actinomycin-D,
which suggested that the mode of action of Biz-2 involved
AR pathways and protein synthesis.
4. Discussion
Given the high incidence of prostate cancer, there is an
urgent need for treatment paradigms that improve prostate
health. Nonsteroidal compounds are an interesting target
for prostate cancer treatment because they do not produce
the undesirable eﬀects associated with traditional steroidal
regimes [12, 39, 41, 42]. The search for nonsteroidal
androgen usually starts by identifying a natural compound
that shows the potential of antiandrogen properties. One
groupofcompoundsthathasreceivedatremendousamount
of attention is the naturally occurring phytoestrogens found
in fruits, vegetables, and teas. These compounds have also
been shown to possess antiandrogenic activity due to their
ability to inhibit and delay prostate cancer [11, 43].
Growth and normal development of the prostate gland
are under the control of androgen acting through interaction
with the AR. The need for new androgenic therapies to
improve prostate function has centered on agents that alter
the AR action. Recently, we reported that the common
Jamaican herbal medicine, Bizzy, contains a putative non-
steroidal compound with bioactivity in both breast and
prostate cancer cells. In this study, we applied the androgen-
dependent LNCaP prostate tumor cell model along with the
androgen-independent DU145 prostate tumor cell model
to ascertain the androgenic eﬀect of this medicinal extract.
Screening of several Bizzy extracts for bioactivity using
severalinvitroassayswasdesignedtoevaluatewhetheranyof
the extracts contained androgenic or antiandrogenic activity
[22]. The study shows that an ether extract of Bizzy (Biz-2)
is the most potent inhibitor of LNCaP cell growth because
it has a high aﬃnity for the AR. At high concentrations,
Biz-2 activates AR-dependent gene expression and induces
apoptosis in LNCaP cells.
We tested the hypothesis that Bizzy nut extract can
modulate prostate activity by using prostate secretion as an
index of prostate function. We observed that the rate of
PSA secreted by LNCaP cells in the presence of Biz-2 was
sharply decreased. Biz-2 modulation of PSA production was
AR-dependent, which implied that Biz-2’s biological eﬀect
may serve as an index of putative phytoandrogen in prostate
cancer cells.14 Journal of Toxicology
The key to a successfully chemopreventive agent against
prostate and other types of cancer will rely on these agents’
ability to induce cell death in tumor cells in a tissue-
dependent and even a receptor-dependent manner. The
search for natural compounds capable of functioning as
potentialchemopreventiveagentsforprostatecancerhasmet
with mixed results [19, 43–45]. Natural chemopreventive
agents as well as anticancer agents function by modulating
one or several major steps in the carcinogenesis pathway.
Naturally occurring agents that could induce apoptosis in
prostate cells in an AR-dependent manner would signal
a new generation of prostate-speciﬁc, chemopreventative
agents. Our Biz-2 extract appears to possess some of the
fundamental activities required for this type of chemo-
preventive agent. We demonstrated that in LNCaP cells,
Biz-2 inhibits at least one family member of the natural
inhibitors of apoptosis (Bcl2), which suggests that Biz-2 may
force cells into the apoptotic pathway. Bcl2 and Bax are
key players in apoptotic events. The ratio of these proteins
determines whether a cell will commit to the apoptosis
pathway. The data provided by this study point to Biz-2
as a putative chemopreventive agent in prostate cells. Biz-
2 showed a time-dependent and dose-dependent increase
in the proapoptotic gene at both the protein and mRNA
levels. The increase in proapoptotic protein was coupled
to morphological signs of apoptosis and to an increase in
enzyme associated with late apoptotic events. Furthermore,
the ability of the antiandrogen ﬂutamide to prevent Biz-
2 induction of both Caspase activity and Bcl2 expression
supports the role of the AR pathway in this process. It
is interesting to note that in the absence of AR, Bizz-2
may possess antiproliferative activity. In the AR-negative
cell, DU145, we observed a greater degree of inhibition of
cell proliferation as compared to AR-positive LNCaP cells.
Correspondently, DU145 had a lower apoptotic index in the
presence of Biz-2. Taken together, these observations suggest
that Biz-2 may elicit antiproliferative activity that does not
require a functional androgen receptor pathway.
In deciphering the role of Biz-2 in prostate function,
it is important to examine the transcriptional eﬀects of
this extract on both estrogen-responsive and androgen-
responsive genes. Androgen, including phytoandrogen, acts
via binding of diﬀerent types of ligands to the AR coalescent
in gene expression. Antagonists, which inhibit the transcrip-
tionalactivityoftheAR,arecurrentlybeingusedaspotential
treatment agents in the ﬁght against prostate cancer. The
involvement of Biz-2 in AR biology was examined using two
parameters:(1)receptorbindingand(2)AR-dependentgene
activation. In classical competition experiments, compo-
nents of our Biz-2 extract are capable of displacing androgen
from the AR. The potency of the putative androgenic
compound in Biz-2 is only thirteen times lower than the
potencyofthesyntheticandrogenR1881.Examinationofthe
transcriptional response of several androgen-regulated genes
reveals a 5-fold induction in mRNA expression following a
24-hour exposure to Biz-2. Levels of expression of NKX3-
1 or PSA, both prostate-speciﬁc genes, were elevated 5-fold
and 10-fold, respectively, by Biz-2. DHT produced a similar
induction in these genes under identical conditions. We
observed that Biz-2 regulated both androgen-dependent and
androgen-independent genes such as Bcl2 and Bax, but was
ineﬀective in regulating the steroid receptor mRNA levels.
This study clearly demonstrated that eﬀects of Biz-2 on
transcriptional activation of AR-dependent genes suggested
that Biz-2 may be androgenic at the levels of transcription.
The biological eﬀects of natural extract containing
putative phytoandrogen or phytoestrogen are multifarious.
Several hypotheses aimed at explaining the diverse action
of these compounds have been proposed. One prevailing
hypothesis for the cancer preventative eﬀect of phytoandro-
gen or phytoestrogen in prostate cancer is the activation of
an apoptotic cascade by components of the natural extract.
In this study, we provide evidence that Biz-2 extract has
the ability to eradicate prostate cancer cells by inducing
apoptosis in an apparent AR-dependent manner. Validation
of these in vitro ﬁndings with an in vivo model system
is warranted. Our ﬁndings highlight the need for a closer
examination of Bizzy nut as a potential source of natural
chemicals that may modulate prostate growth and function.
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